Background Chronic kidney disease (CKD) poses a significant health risk in contemporary
society. Current CKD treatments primarily involve renin-angiotensin-aldosterone system …

Finerenone, a selective and nonsteroidal antagonist of the mineralocorticoid receptor, has
received regulatory approval with the indication of cardiorenal protection in patients with …

As people age, they tend to spend more time indoors, and the colours in their surroundings
may significantly impact their mood and overall well‐being. However, there is a lack of …

Aims To perform dose–exposure–response analyses to determine the effects of finerenone
doses. Materials and Methods Two randomized, double‐blind, placebo‐controlled phase 3 …

Abstract Background and Objectives In vitro and in vivo studies were performed with the
novel, selective, nonsteroidal mineralocorticoid receptor antagonist finerenone to assess the …

Abstract Background: Mineralocorticoid receptor antagonists (MRAs) protect cardiorenal
function by robust anti-inflammatory and antifibrotic functions beyond classical functions of …

Abstract Background and Objectives Finerenone is a nonsteroidal mineralocorticoid
receptor antagonist that reduces the risk of adverse kidney and cardiovascular outcomes in …

Abstract Background Mineralocorticoid receptor antagonists (MRAs) were shown to delay
chronic kidney disease (CKD) progression in patients with hypertension and/or heart failure …

The nonsteroidal MRA finerenone could improve renal and cardiac outcomes further in
diabetics with kidney disease when added to renin-angiotensin system inhibitors …

Abstract Background Mineralocorticoid receptor antagonists (MRAs) have emerged as
potential therapy to target the underlying arrhythmogenic substrate in atrial fibrillation (AF) …